𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of Hypotony in Noninfectious Uveitis

✍ Scribed by Daniel, Ebenezer; Pistilli, Maxwell; Pujari, Siddharth S.; Kaçmaz, R. Oktay; Nussenblatt, Robert B.; Rosenbaum, James T.; Suhler, Eric B.; Thorne, Jennifer E.; Foster, C. Stephen; Jabs, Douglas A.; Levy-Clarke, Grace A.; Kempen, John H.

Book ID
123175932
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
736 KB
Volume
119
Category
Article
ISSN
0161-6420

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[Developments in Ophthalmology] New Trea
[Developments in Ophthalmology] New Treatments in Noninfectious Uveitis Volume 51 || Rituximab for Noninfectious Uveitis
✍ Miserocchi, E.; Modorati, G.; Foster, C.S. 📂 Article 📅 2012 🏛 S. KARGER AG 🌐 English ⚖ 153 KB

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intrao

[Developments in Ophthalmology] New Trea
[Developments in Ophthalmology] New Treatments in Noninfectious Uveitis Volume 51 || The Gold Standard of Noninfectious Uveitis: Corticosteroids
✍ Miserocchi, E.; Modorati, G.; Foster, C.S. 📂 Article 📅 2012 🏛 S. KARGER AG 🌐 English ⚖ 543 KB

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intrao

[Developments in Ophthalmology] New Trea
[Developments in Ophthalmology] New Treatments in Noninfectious Uveitis Volume 51 || Anti-Tumor Necrosis Factor-a Agents in Noninfectious Uveitis
✍ Miserocchi, E.; Modorati, G.; Foster, C.S. 📂 Article 📅 2012 🏛 S. KARGER AG 🌐 English ⚖ 313 KB

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intrao